WGS
Overvalued by 200.6% based on the discounted cash flow analysis.
Market cap | $1.34 Billion |
---|---|
Enterprise Value | $1.29 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $-7.23 |
Beta | 2.38 |
Outstanding Shares | 26,617,955 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -11.29 |
---|---|
PEG | 14.05 |
Price to Sales | 5.64 |
Price to Book Ratio | 6.26 |
Enterprise Value to Revenue | 4.84 |
Enterprise Value to EBIT | -23.71 |
Enterprise Value to Net Income | -16 |
Total Debt to Enterprise | 0.04 |
Debt to Equity | 0.2 |
No data
No data
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and g...